McCord Opens Boston Office with Acquisition of Former GlaxoSmithKline GMP Life Science Facility
McCord to Continue Life Science Expansion in Boston and Houston
HOUSTON, Texas – September, XX, 2020 –McCord announces the opening of its Boston office with the acquisition of 30 Bearfoot, a 64,736 sq. ft. GMP biomanufacturing and research and development (R&D) facility, formerly home to GlaxoSmithKline (GSK), in Boston’s MetroWest Life Sciences Cluster. McCord acquired 30 Bearfoot from a subsidiary of Alexandria Real Estate Equities who owned the property for 15 years. The acquisition sets the stage for McCord’s continued growth in Boston and Houston’s life science spaces.
McCord will implement extensive renovations to 30 Bearfoot to provide a modern aesthetic and environment fit for mission critical life science companies. Through the renovations McCord aims to bring its signature tenant-centric experience to 30 Bearfoot, enabling life science companies to optimize their manufacturing process while recruiting and retaining top talent.
“Our approach to real estate is intentional. As we evaluate existing buildings for repositioning or land for new development, we look at how we can positively impact not only the asset, but the surrounding community,” said President of McCord, Ryan McCord. “Boston, just like Houston, is a hub of innovation. Now more than ever it is critical for us to deliver human-centric real estate experiences in these innovation hubs to promote further advancements within the medical and life science fields.”
The acquisition of 30 Bearfoot closely follows the announcement of Shawn Cloonan, former Texas Medical Center Chief Operating Officer and life science industry expert, joining McCord’s leadership team. It also follows recent disclosure of a new 101,000 sq. ft. medical office building planned for McCord’s 4,200-acre master planned development, Generation Park. With its proximity to the Texas Medical Center, Bush Intercontinental Airport, multiple colleges developing talent, excellent primary education, and beautiful master planned neighborhoods, Generation Park is poised to take on Houston’s life science growth.
“The past months have highlighted the importance and complexity of biology,” said Boston-based partner, Quentin Hart. “At McCord, we understand the importance of creating spaces that can facilitate rapid development and production of discoveries that are vital to the future of biomedical advances.”
30 Bearfoot, formerly home to GSK, is in the booming MetroWest Life Science Cluster west of Boston’s renowned Kendall Square. MetroWest is home to leading life science companies such as AbbVie, Boston Scientific, Sanofi Genzyme, and Sunovion.
For more information and leasing inquiries for 30 Bearfoot Rd, Northborough, MA, contact email@example.com. For more information about Generation Park’s life sciences opportunities, including medical office space, contact firstname.lastname@example.org and email@example.com. To learn more about McCord, visit mccord.com.
McCord is a Houston and Boston-based opportunistic real estate company with a longstanding track record of creating substantial value through the acquisition, development, and management of office, industrial, land, single family, and multifamily assets. Since 1973, McCord has acquired or developed over $3 billion in successful projects across the United States. To learn more, visit mccord.com.
About Generation Park
Generation Park, an innovative business and lifestyle destination, is a master-planned enterprise in Houston, Texas. Over a quarter the size of Manhattan and with convenient access to all major land, air and sea transportation corridors in Houston, Generation Park is driving the expansion of one of Houston fastest growing economic and residential centers, Lake Houston. Generation Park’s flagship entertainment and lifestyle destination, Redemption Square, is home to a growing collection of curated retailers, restaurants, and many future developments. For more information, please visit generationpark.com.